Research indicates that over 50% of parents with ADHD have a child diagnosed with the same condition. The heritability of ADHD raises concerns, especially since symptoms like impaired executive functioning and emotional regulation can impact how parents manage therapies for their children with ADHD. Studies suggest that parental ADHD is linked to poorer developmental and treatment outcomes for these children, yet some have questioned whether addressing parental ADHD affects child outcomes.

Read More

A six-year study led by Dr. Andrea Chronis-Tuscano at the University of Maryland, College Park, aimed to assess the effectiveness of combining ADHD medication with an evidence-based behavioral parenting intervention (I-BPT) for parents with ADHD. The study sought to determine if this approach would yield more favorable outcomes for children compared to I-BPT alone.

The research involved 120 parent-child dyads, randomly split into two groups: one receiving only I-BPT and the other receiving stimulant medication (MAS-XR) prior to and during I-BPT. Medication dosages started at 20mg/day and could increase to a maximum of 60mg/day based on tolerability. Approximately 71% of participants continued the medication at an average dosage of 35mg/day. The stimulant response rate was 85%, consistent with previous adult trials. Notably, the participating children had not received any ADHD medication prior to the trial.

Participants included predominantly female parents, with a third identifying as Black or Hispanic. The average family income was $150,000, and two-thirds of child participants were male, averaging six years old.

I-BPT incorporates cognitive-behavioral therapy and organizational skills training, focusing on assertiveness, discipline strategies, and parent-child interactions. The primary outcome measure was the severity of the child's ADHD symptoms, assessed weekly using standardized scales.

Results indicated that parents treated with medication in conjunction with I-BPT experienced greater reductions in ADHD symptom severity for themselves and their children compared to those receiving I-BPT alone. Specifically, the clinical severity scores of children in the medication group decreased from an average of 4.52 to 3.67, a 19% improvement, while scores decreased from 4.31 to 3.96, an 8% improvement, in the I-BPT-only group. Parents in the medication group also experienced a significant reduction in their ADHD severity, decreasing from 3.52 to 2.96.

Both groups saw improvements in parenting behaviors, but those who received medication were more likely to engage in positive reinforcement strategies and follow through on disciplinary actions. These findings suggest that medication can enhance the effectiveness of behavioral interventions.

The researchers advocate for future studies to explore if similar outcomes could apply to lower-income families and those facing barriers to treatment. While 11% of trial participants had an annual income under $25,000, there is a need to understand better which families stand to benefit most from the combined approach.

Overall, the study presents promising data, indicating that concurrent treatment of parental ADHD with medication can lead to improved outcomes for both parents and children with ADHD.